Mediators of Inflammation / 2014 / Article / Tab 1

Research Article

The Possible Role of the Novel Cytokines IL-35 and IL-37 in Inflammatory Bowel Disease

Table 1

Demographic and clinical characteristics of IBD patients.

Patients numberSexAge atDiseaseDisease
extent
Disease
activity
Current therapy
diagnosisduration
(years)(months)

Mayo score

UC1F464E27Mesalazine
UC2M2970E312Mesalazine, corticosteroids
UC3M252E39Mesalazine, corticosteroids
UC4F5110E311Mesalazine, corticosteroids
UC5M5712E15Mesalazine,
UC6M346E26Mesalazine,
UC7F28168E23Mesalazine,
UC8M343E311Mesalazine, corticosteroids
UC9F2840E211Mesalazine, corticosteroids, and AZA
UC10M597E311Mesalazine, corticosteroids
UC11M241E38Mesalazine, corticosteroids
UC12F271E14Mesalazine, enema
UC13M271E13Mesalazine
UC14M582E212Mesalazine, corticosteroids
UC15M652E25Mesalazine
UC16F152E211Mesalazine, corticosteroids
UC17M2212E36Mesalazine
UC18M371E33Mesalazine
UC19F631E38Mesalazine
UC20F285E37Mesalazine, enema
Average (SEM)37.85  (3.48)17.50  (8.76)7.65  (0.72)

CDAI score

CD1M602L17Mesalazine, corticosteroids, and AZA
CD2M39180L16Mesalazine, AZA
CD3M285L28Mesalazine, corticosteroids
CD4F261L39Mesalazine, corticosteroids
CD5M4960L49Mesalazine, corticosteroids
CD6M503L36Mesalazine
CD7M226L17Mesalazine, corticosteroids
Average (SEM)39.15  (5.44)36.71  (25.18)7.43  (0.48)

UC: ulcerative colitis; CD: Crohn’s disease; E1: proctitis; E2: leftsided colitis; E3: pancolitis; L1: ileal; L2: colonic; L3: ileocolonic; L4: upper GI involvement; AZA: azathioprine.